User Image Cart Icon 0 Search Image

Cross Link Breakers

  1. Advanced glycation end-product cross-link breakers: a novel approach to cardiovascular pathologies related to the aging process
  2. Cross-link breakers as a new therapeutic approach to cardiovascular disease
  3. Potential clinical utility of advanced glycation end product cross-link breakers in age-and diabetes-associated disorders
  4. Collagen cross-link breakers: a beginning of a new era in the treatment of cardiovascular changes associated with aging, diabetes, and hypertension
  5. Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein AI
  6. The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation
  7. Potential Usefulness of AGE Cross–Link Breakers for Modulating the Progression of AMD
  8. Advanced glycation end-product cross-link breakers: a novel therapeutic pathway for cardiovascular disease
  9. Cross-link Breakers and Inhibitors
  10. Cleavage of in vitro and in vivo formed lens protein cross-links by a novel cross-link breaker
  11. Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links
  12. In vitro antiglycation and cross-link breaking activities of Sri Lankan low-grown orthodox orange pekoe grade black tea (Camellia sinensis L)
  13. Characteristics, formation, and pathophysiology of glucosepane: a major protein cross-link
  14. Inhibitors and breakers of advanced glycation endproducts (AGEs): a review
  15. Effect of the age cross-link breaker alagebrium on anterior segment physiology, morphology, and ocular age and rage
  16. Restraining cross-links responsible for the mechanical properties of collagen fibers: natural and artificial
  17. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart
  18. Therapeutic options to reduce advanced glycation end products in patients with diabetes mellitus: A review
  19. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes
  20. Biochemical process of AGEs formation in complications of hyperglycemia-induced diabetes and its pathological damage effects: A possible target for new drugs
  21. Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease
  22. The breakdown of preformed advanced glycation end products reverses erectile dysfunction in streptozotocin‐induced diabetic rats: Preventive versus curative …
  23. Crosslink breakers: a new approach to cardiovascular therapy
  24. AGE, RAGE, and ROS in diabetic nephropathy
  25. Laser Sub–Fractionation to Assess the Elasticity of Ageing Human Bruch’s Membrane: Reversal Implications for AMD
  26. Diabetic heart disease
  27. Advanced glycation end‐products (AGEs) and heart failure: pathophysiology and clinical implications
  28. Novel cross-link breaker based on zwitterion structure: Synthesis, structure and druggability studies
  29. Advanced Glycation End Products in Diabetes‐Associated Atherosclerosis and Renal Disease: Interventional Studies
  30. Advanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling
  31. The diabetic myocardium
  32. Arterial stiffness and cardiovascular therapy
  33. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys
  34. Treating diastolic heart failure with AGE crosslink breakers: thinking outside the heart failure box
  35. Synthesis and Evaluation of Novel [1,2,4]Triazolo[5,1‐c][1,2,4]‐triazines and Pyrazolo[5,1‐c][1,2,4]triazines as Potential Antidiabetic Agents
  36. Consensus ensemble neural network modeling of Maillard reaction inhibitors
  37. Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus
  38. Advanced Glycation End Product Cross‐Linking: Pathophysiologic Role and Therapeutic Target in Cardiovascular Disease
  39. Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications
  40. The AGE/RAGE axis in diabetes‐accelerated atherosclerosis
  41. β‐Amyloid peptide potentiates inflammatory responses induced by lipopolysaccharide, interferon‐γ and ‘advanced glycation endproducts’ in a murine microglia cell …
  42. Do advanced glycation end products contribute to the development of long-term diabetic complications?
  43. AGE-RAGE and AGE Cross-link interaction: important players in the pathogenesis of diabetic kidney disease
  44. Clinical potential of advanced glycation end-product inhibitors in diabetes mellitus
  45. 925 ARE ADVANCED GLYCATION END PRODUCTS ASSOCIATED WITH MACROVASCULAR DISEASE IN TYPE 2 DIABETES MELLITUS?
  46. Pharmacological modulation of arterial stiffness
  47. The Unique Reactivity of N-Phenacyl-Derived Thiazolium Salts Toward α-Dicarbonyl Compounds
  48. Therapeutic modulation of aortic stiffness
  49. Screening of herbal medicines from China with inhibitory activity on advanced glycation end products (AGEs) formation (VI)
  50. Screening of herbal medicines from China and Vietnam with inhibitory activity on advanced glycation end products (AGEs) formation (IV)
  51. Aging of the Vasculature and Related Systems
  52. Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products
  53. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease
  54. New therapies for advanced glycation end product nephrotoxicity: current challenges
  55. Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs?
  56. Advanced Glycation Endproducts,(AGEs): Formation, Complication and Pharmacological Evaluation to Its Inhibition
  57. Fibrosis, enzymatic and non-enzymatic cross-links in hypertensive heart disease
  58. Advanced glycation end products inhibitor
  59. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases
  60. The breakdown of preformed peritoneal advanced glycation end products by intraperitoneal alagebrium
  61. How drugs influencing central blood pressure prevent atherosclerosis complications?
  62. Methylglyoxal, oxidative stress, and aging
  63. The breakdown of pre‐existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes
  64. The impracticality of biomedical rejuvenation therapies: translational and pharmacological barriers
  65. Molecular basis of arterial stiffening: role of glycation–a mini-review
  66. The next generation of diabetic nephropathy therapies: an update
  67. The ultimate AGE inhibitors
  68. Advanced glycation: implications in tissue damage and disease
  69. Therapeutic interventions in the glyc (oxid) ation pathway
  70. Diabetes and arterial stiffening
  71. Advanced glycation end products and diabetic nephropathy
  72. The role of advanced glycation end products in progression and complications of diabetes
  73. Transition metal‐mediated glycoxidation accelerates cross‐linking of β‐amyloid peptide
  74. Introduction of hyperglycemia and dyslipidemia in the pathogenesis of diabetic vascular complications
  75. Naturally occurring inhibitors against the formation of advanced glycation end-products
  76. Effects of chebulic acid on advanced glycation endproducts-induced collagen cross-links
  77. The deconvolution of diastole
  78. Large artery stiffness and brain health: Insights from animal models
  79. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis
  80. Advanced glycation end products
  81. Functional effects of alagebrium (alt-711)–isolated rat carotid artery
  82. Natural inhibitors of advanced glycation end‐products
  83. The advanced glycation end product-lowering agent ALT-711 is a low-affinity inhibitor of thiamine diphosphokinase
  84. More than genes and cells: drug discovery in the ECM
  85. What the dead can teach the living: systemic nature of heart failure with preserved ejection fraction
  86. Advanced glycation end-products and arterial stiffness in hypertension
  87. Polyclonal antibodies inhibit the glycation‐induced inactivation of bovine Cu, Zn‐superoxide dismutase
  88. Advanced glycation endproducts—role in pathology of diabetic complications
  89. The role of advanced glycation end products in the development of atherosclerosis
  90. The role of advanced glycation end products in various types of neurodegenerative disease: a therapeutic approach
  91. Uremic toxicity of advanced glycation end products in CKD
  92. Atherogenesis and Advanced Glycation: Promotion, Progression, and Preventiona
  93. The role of collagen crosslinks in ageing and diabetes-the good, the bad, and the ugly
  94. The effects of the Maillard reaction on the physical properties and cell interactions of collagen
  95. Advanced glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications Study
  96. A novel improved therapy strategy for diabetic nephropathy: targeting AGEs
  97. Diabetic cardiomyopathy—What do we know about it?
  98. Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation
  99. Multiligands/Rage Axis: an Emerging Actor in Tumour Angiogenesis
  100. Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease
  101. Role of glycation in aging
  102. RAGE: a new pleiotropic antagonistic gene?
  103. Urinary proteomics in diabetes and CKD
  104. Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines
  105. Glycation of high-density lipoprotein in type 2 diabetes mellitus
  106. The causes and consequences of low levels of high density lipoproteins in patients with diabetes
  107. Reducing arterial stiffness and wave reflection–Quest for the Holy Grail?
  108. Role of advanced glycation end products in diabetic nephropathy
  109. Drug therapy for the cardiac complications of diabetes
  110. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future
  111. Glycation, carbonyl stress and AGEs inhibitors: a patent review
  112. Hypertension and diabetes
  113. Current perspectives on the health risks associated with the consumption of advanced glycation end products: recommendations for dietary management
  114. Future strategies to prevent renal microvascular disease complications in diabetes
  115. Molecular targets of diabetic cardiovascular complications
  116. Prevention of non-enzymatic glycosylation (glycation): Implication in the treatment of diabetic complication
  117. Pathophysiology, genetic, and therapy of arterial stiffness
  118. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension
  119. Methylglyoxal-induced mitochondrial dysfunction in vascular smooth muscle cells
  120. Methylglyoxal and advanced glycation endproducts: new therapeutic horizons?
  121. Left ventricular diastolic dysfunction in dialysis patients assessed by novel speckle tracking strain rate analysis: prevalence and determinants
  122. Alagebrium (ALT-711) improves the anti-hypertensive efficacy of nifedipine in diabetic-hypertensive rats
  123. Alagebrium in combination with exercise ameliorates age-associated ventricular and vascular stiffness
  124. More than genes and cells: Drug discovery in the extracellular matrix (ECM)
  125. Arterial stiffness, pulse pressure, and cardiovascular disease—is it possible to break the vicious circle?
  126. Oxidative stress in diabetes and Alzheimer’s disease
  127. The role of advanced glycation end products in diabetic vascular complications
  128. New therapeutic avenues for age-related macular degeneration: targeting Bruch’s membrane
  129. Advanced glycation end products: role in pathology of diabetic cardiomyopathy
  130. Potential of collagen cross-linking therapies to mediate tendon mechanical properties
  131. The aging hypertensive heart: a brief update
  132. Therapeutic effect of combination of alagebrium (ALT-711) and sildenafil on erectile function in diabetic rats
  133. Blocking Gastrointestinal Absorption of AGEs
  134. The clinical relevance of ageing
  135. Induced pluripotent stem (iPS) cells inhibit apoptosis and fibrosis in streptozotocin-induced diabetic rats
  136. Republished paper: arterial stiffness in chronic kidney disease: causes and consequences
  137. Mechanisms of Diabetic Complications Nephropathy as Related to Perspectives of Treatment
  138. Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease
  139. Anti-AGEing defences against Alzheimer’s disease
  140. Melatonin is not a carbonyl scavenger
  141. Below the Radar: Advanced Glycation End Products that Detour “around the side”: Is HbA1c not an accurate enough predictor of long term progression and …
  142. Newer insights in drugs inhibiting formation and accumulation of advanced glycation end products.
  143. The effect of an advanced glycation end-product crosslink breaker and exercise training on vascular function in older individuals: a randomized factorial design trial
  144. Glucose as an agent of post-translational modification in diabetes—New cardiac epigenetic insights
  145. AGE-RAGE axis blockade in diabetic nephropathy: current status and future directions
  146. Matrix biology of abdominal aortic aneurysms in diabetes: mechanisms underlying the negative association
  147. The role of AGEs and AGE inhibitors in diabetic cardiovascular disease
  148. Stagnation and the critical need for hypertension subtyping
  149. Does accumulation of advanced glycation end products contribute to the aging phenotype?
  150. Potential new therapeutic agents for diabetic kidney disease
  151. The aorta and resistant hypertension
  152. Targeting advanced glycation with pharmaceutical agents: where are we now?
  153. Hormetic triggers for intervention in aging, disease and trauma
  154. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications
  155. Glycoxidative stress in aging and pathology
  156. Role of advanced glycation end products in carcinogenesis and their therapeutic implications
  157. Serum carboxymethyllysine concentrations are reduced in diabetic men with abdominal aortic aneurysms: Health In Men Study
  158. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension
  159. Early-and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics
  160. Mechanisms Involved in Premature Aging in the Heart—Is There an Implication for Cardiac Surgery?
  161. The pulsatile component of blood pressure–Its role in the pathogenesis of atherosclerosis
  162. Role of advanced glycation endproduct (AGE)-receptor for advanced glycation endproduct (RAGE) axis in cardiovascular disease and its therapeutic intervention
  163. Cardiac fibrosis and aging
  164. The role of AGEs in cardiovascular disease
  165. Oxidative stress and aging: is methylglyoxal the hidden enemy?
  166. Alagebrium chloride, a novel AGE cross linkage breaker, inhibits neointimal proliferation after carotid balloon injury in diabetic animal model
  167. The question is, my dear watson, why did the dog not bark?: The joslin 50-year medalist study
  168. Cinnamon bark proanthocyanidins as reactive carbonyl scavengers to prevent the formation of advanced glycation endproducts
  169. Inhibition of advanced glycation end-product formation by lutein from Tagetes erecta
  170. Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein AI
  171. The therapeutic effect of ALT-711 on erectile function in rats treated with high-level AGEs (advanced glycation end products) containing diet
  172. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease
  173. Diastolic disturbances in diabetes mellitus
  174. The Implications of Fruit and Vegetable Consumption in Patients with Diabetes
  175. Does angiotensin receptor blockade improve outcomes in patients with heart failure and preserved ejection fraction? Results of the I-PRESERVE study
  176. Reactions in glass ionomer cements: V. Effect of incorporating tartaric acid in the cement liquid
  177. Soft-tissue wound healing by anti-advanced glycation end-products agents
  178. Glycative stress and anti-aging: 14. Regulation of Glycative stress. 2. Inhibition of the AGE production and accumulation
  179. Role of hyperglycemia-induced advanced glycation end product (AGE) accumulation in atherosclerosis
  180. Decreasing Arterial Stiffness and/or Wave Reflections Independently of Mean Arterial Pressure: Effect of Antihypertensive Drugs (Part 1)
  181. Dynamic changes in myocardial matrix and relevance to disease: translational perspectives
  182. Resurrecting the dead (molecules)
  183. New insights in the pharmacological therapy of arterial hypertension
  184. Protein glycation: a firm link to endothelial cell dysfunction
  185. Cellular mechanisms for diastolic dysfunction in the human heart
  186. Arterial stiffness in chronic kidney disease: an update
  187. Targeting AGEs signaling ameliorates central nervous system diabetic complications in rats
  188. Advanced glycation end‐products, anti‐hypertensive treatment and diastolic function in patients with hypertension and diastolic dysfunction
  189. Inhibition of renin-angiotensin system and advanced glycation end products formation: a promising therapeutic approach targeting on cardiovascular diseases
  190. Heat stable inhibitors of protein cross-linking from Sri Lankan medicinal plants
  191. Arterial stiffness, cognitive impairment and dementia: confounding factor or real risk?
  192. Can you reduce your AGE?: Strategies to prevent AGE accumulation in diabetes
  193. Are Finger Skin Fluorophores Other Than Advanced Glycation End Products (AGEs) Associated With Impaired Musculoskeletal Properties?
  194. Advanced glycosylated end products derived from external sources contribute to diabetic complications
  195. Pyrazolotriazines: biological activities, synthetic strategies and recent developments
  196. Novel therapeutics for diabetic micro-and macrovascular complications
  197. Effects of uwhangchungsimwon on arterial stiffness
  198. Type 2 diabetes—implications for macrovascular mechanics and disease
  199. Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients
  200. Arterial stiffness and coronary ischemic disease
  201. Heart failure with preserved ejection fraction and future pharmacological strategies: a glance in the crystal ball
  202. Recent advances in understanding the biochemical and molecular mechanism of diabetic cardiomyopathy
  203. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression
  204. An anti-glycating property roots ethanol and methanol extracts of Withania somnifera on in vitro glycation of elastin protein
  205. Antihypertensive therapy and de-stiffening of the arteries
  206. Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy?
  207. Role of Smad1 in diabetic nephropathy: molecular mechanisms and implications as a diagnostic marker
  208. Role of advanced glycation end products in cardiovascular disease
  209. Glycated proteome: From reaction to intervention
  210. Mechanical properties of normal and diseased cerebrovascular system
  211. Browsed by Tag: senolytics
  212. Molecular mechanisms of diabetic vascular complications
  213. Heart failure highlights in 2011
  214. Long-term exercise training attenuates age-related diastolic dysfunction: association of myocardial collagen cross-linking
  215. Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions
  216. Cellular mechanisms and consequences of glycation in atherosclerosis and obesity
  217. Heart failure with preserved ejection fraction: current management and future strategies
  218. KIOM-79, an inhibitor of AGEs–protein cross-linking, prevents progression of nephropathy in Zucker diabetic fatty rats
  219. Hyperglycemia and the pathobiology of diabetic complications
  220. Increased collagen, per se, may not affect left ventricular function in spontaneously hypertensive rats
  221. Heart failure with preserved ejection fraction: uncertainties and dilemmas
  222. Comparative study of antioxidant, metal chelating and antiglycation activities of Momordica charantia flesh and pulp fractions.
  223. Cleaving effect of pomegranate (Punica granatum) extract on crosslink derived from advanced glycation endproducts
  224. Relationship between tissue glycation measured by autofluorescence and pulse wave velocity in young and elderly non-diabetic populations
  225. Browsed by Tag: Lysosomes
  226. Browsed by Tag: allotopic expression
  227. Browsed by Tag: Lysosomal dysfunction
  228. Browsed by Tag: Mitochondrial mutations
  229. SENS: Progress in the Fight Against Age-Related Diseases–Article by Nicola Bagalà and Steve Hill
  230. Browsed by Tag: MitoSENS crowdfunding campaign
  231. Browsed by Tag: Kizoo Technology Ventures
  232. Browsed by Tag: Dr. Kelsey Moody
  233. Browsed by Tag: Professor Judy Campisi
  234. Growth factors, AGEing, and the diabetes link in Alzheimer’s disease
  235. Do advanced glycation end products and its receptor play a role in pathophysiology of hypertension?
  236. Advanced glycation endproducts: from precursors to RAGE: round and round we go
  237. Diabetic cardiomyopathy
  238. Optimal treatment of hypertension in the elderly: A Korean perspective
  239. Optimal treatment of hypertension with diastolic heart failure
  240. Receptor for advanced glycation end products and the cardiovascular complications of diabetes and beyond: lessons from AGEing
  241. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines
  242. Dicarbonyls linked to damage in the powerhouse: glycation of mitochondrial proteins and oxidative stress
  243. Aortic stiffness: current understanding and future directions
  244. Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging
  245. 50 Year Medalists’ Biochemistry Clue Researchers to the Source of Complications or” The Question Is, My Dear Watson, Why Did the Dog Not Bark?
  246. Glycoxidation of biological macromolecules: a critical approach to halt the menace of glycation
  247. Facts and numbers on epidemiology and pharmacological treatment of heart failure with preserved ejection fraction
  248. Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases
  249. Arterial stiffness in renal patients: an update
  250. Pathogenesis of elevated peripheral pulse pressure: some reflections and thinking forward
  251. Treatment and control of high blood pressure in adults
  252. Arterial Stiffness and Coronary Ischemic
  253. Inhibition of the receptor for advanced glycation end-products in acute respiratory distress syndrome: a randomised laboratory trial in piglets
  254. Advanced glycation end products: key players in skin aging?
  255. Advanced glycation endproducts: activators of cardiac remodeling in primary fibroblasts from adult rat hearts
  256. Natural products as potential inhibitors of Advanced Glycation Endproducts (AGEs) and modulators of autophagy
  257. Ultrasonic detection of the anisotropy of protein cross linking in myocardium at diagnostic frequencies
  258. Mechanisms, pathophysiology, and therapy of arterial stiffness
  259. Protein glycation during aging and in cardiovascular disease
  260. Arterial aging: is it an immutable cardiovascular risk factor?
  261. Concerns about clinical efficacy and safety of warfarin in diabetic patients with atrial fibrillation
  262. Advanced glycation/glycoxidation endproduct carboxymethyl-lysine and incidence of coronary heart disease and stroke in older adults
  263. Collagen in its fibrillar state is protected from glycation
  264. Mechanisms of Diabetic Complications (Nephropathy) as Related to Perspectives of Treatment
  265. Prehypertension and risk of cardiovascular disease
  266. Ageing of the conduit arteries
  267. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering
  268. Investigation of the mechanism (s) involved in decreasing increased fibrinogen activity in hyperglycemic conditions using L-lysine supplementation
  269. Left ventricular hypertrophy regression and allopurinol: more questions than answers
  270. Aldose reductase pathway inhibition improved vascular and C-fiber functions, allowing for pressure-induced vasodilation restoration during severe diabetic …
  271. Erectile dysfunction and associated risk factors in male patients with ischemic stroke: A cross-sectional study
  272. Diastolic heart failure: mechanisms and controversies
  273. Aged garlic has more potent antiglycation and antioxidant properties compared to fresh garlic extract in vitro
  274. Inhibition of Protein Glycation by Combined Antioxidant and Antiglycation Constituents from a Phenolic Fraction of Sage (Salvia officinalis L.)
  275. Neuronal cell death and regeneration in diseases associated with advanced glycation end-products accumulation
  276. Advanced glycation end-products: a review
  277. Pharmacological evaluation of novel alagebrium analogs as methylglyoxal scavengers in vitro in cardiac myocytes and in vivo in SD rats
  278. Heart failure with preserved ejection fraction: a clinical dilemma
  279. Are AGEs Implicated in Atherosclerosis?
  280. Nitric oxide and the regulation of large artery stiffness: from physiology to pharmacology
  281. RAGE: a multi-ligand receptor unveiling novel insights in health and disease
  282. Browsed by Tag: Oisin Biotechnologies
  283. Regenerative therapies for diabetic microangiopathy
  284. URINARY PROTEOMICS IN DIABETES AND CHRONIC RENAL DISEASE
  285. Collagen peptide simulated bending after applied axial deformation
  286. Heart failure with preserved ejection fraction: current understanding and emerging concepts
  287. Mechanisms of diabetic vasculopathy: an overview
  288. Disturbance of macro-and microcirculation: relations with pulse pressure and cardiac organ damage
  289. Glycation of human high density lipoprotein by methylglyoxal: effect on HDL-paraoxonase activity
  290. Review article New therapeutic goals–new drugs in heart failure treatment
  291. Stochastic non-enzymatic modification of long-lived macromolecules-A missing hallmark of aging
  292. Flavonoids derived from buckwheat hull can break advanced glycation end-products and improve diabetic nephropathy
  293. Antiamylase, Antiglucosidase, and Antiglycation Properties of Millets and Sorghum from Sri Lanka
  294. Glycation-induced modification of tissue-specific ECM proteins: A pathophysiological mechanism in degenerative diseases
  295. Causes and characteristics of diabetic cardiomyopathy
  296. Assessing wide pulse pressure hypertension: data beyond the guidelines
  297. The role of advanced glycation end products on sarcoplasmic reticulum calcium handling during diabetic cardiomyopathy
  298. Glycation—a sweet tempter for neuronal death
  299. Plasticity of kidney cells: role in kidney remodeling and scarring
  300. Chasing the wave. Unfashionable but important new concepts in arterial wave travel
  301. Cardiovascular effects of 1 year of alagebrium and endurance exercise training in healthy older individuals
  302. Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs
  303. Advanced glycation end products, rage, and aging
  304. Age-and diabetes-induced regulation of oxidative protein modification in rat brain and peripheral tissues: Consequences of treatment with antioxidant pyridoindole
  305. Collagen as a double-edged sword in tumor progression
  306. Advanced glycation end products: a link between periodontitis and diabetes mellitus?
  307. Browsed by Tag: mtDNA
  308. Exercise training initiated in late middle age attenuates cardiac fibrosis and advanced glycation end-product accumulation in senescent rats
  309. The failing diabetic heart: focus on diastolic left ventricular dysfunction
  310. Translational applications of glucose metabolism in abdominal aortic aneurysm
  311. Vascular compliance in the cardiometabolic syndrome
  312. Association between systemic arterial stiffness and age-related macular degeneration
  313. Advanced Glycation–New AGE Focus for Diabetes
  314. Why We Age: From Healthy Aging
  315. Sex-specific differences in cardiac maladaptation to hypertension and arterial stiffening
  316. Diabetic microvascular disease: an endocrine society scientific statement
  317. The protective effect of aminoguanidine on erectile function in diabetic rats is not related to the timing of treatment
  318. Metabolic memory in the autonomic neuropathy of diabetes: implications for pathogenesis and patient care
  319. Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation
  320. Ventriculovascular coupling in systolic and diastolic heart failure
  321. Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options
  322. The relationship between resistant hypertension and arterial stiffness
  323. Association of advanced glycation end products, evaluated by skin autofluorescence, with lifestyle habits in a general Japanese population
  324. Advanced glycation end products and the kidney
  325. LR-90 a new advanced glycation endproduct inhibitor prevents progression of diabetic nephropathy in streptozotocin-diabetic rats
  326. Decreasing Arterial Stiffness and/or Wave Reflections Independently of Mean Arterial Pressure: Effect of Non-antihypertensive Drugs (Part 2)
  327. The role of inflammaging and advanced glycation end products on paratonia in patients with dementia
  328. Aging: Drugs to eliminate methylglyoxal, a reactive glucose metabolite, and advanced glycation endproducts
  329. Inhibition of advanced glycation end-product formation and antioxidant activity by extracts and polyphenols from Scutellaria alpina L. and S. altissima L.
  330. Therapeutic potential of DNA-aptamers raised against AGE-RAGE axis in diabetes-related complications
  331. Browsed by Tag: SASP
  332. Pathological role of D-amino acid-containing proteins and advanced glycation end products in the development of age-related macular degeneration
  333. Browsed by Tag: Senescence Associated Secretory Phenotype
  334. Molecular mechanisms of diabetic vasculopathy
  335. Role of advanced glycation end products in hypertension and atherosclerosis: therapeutic implications
  336. Browsed by Tag: SRF
  337. Exercise Intolerance in Diastolic Heart Failure
  338. Scrutiny of cardiovascular risk factors by assessing arterial stiffness in erectile dysfunction patients
  339. Aortic stiffness and disease: location is key
  340. Aging and glycoxidant stress
  341. Experimental models for the study of the cellular and molecular pathophysiology of Peyronie’s disease
  342. Arterial stiffness: methods of measurement, physiologic determinants and prediction of cardiovascular outcomes
  343. The status of glycation in protein aggregation
  344. A CURRENT REVIEW ON THIAZOLE NUCLEUS & IT’S DERIVATIVES
  345. Aortic stiffness and calcification in men in a population-based international study
  346. Aging of myocardial collagen
  347. Advanced Glycation End Products Are Associated With Inflammation and Endothelial Dysfunction in HIV
  348. Nondiabetic glucometabolic status and progression of aortic stiffness: the Whitehall II study
  349. Interventions against degenerative aging
  350. Pulse pressure partially explains the higher incidence of cardiovascular disease associated with advanced glycation endproducts and low-grade inflammation …
  351. Oral L-carnitine supplementation increases trimethylamine-N-oxide but reduces markers of vascular injury in hemodialysis patients
  352. Evidence for the Formation of Adducts and S-(Carboxymethyl)cysteine on Reaction of α-Dicarbonyl Compounds with Thiol Groups on Amino Acids, Peptides, and …
  353. Slowing the aging process
  354. The hypertension paradox—more uncontrolled disease despite improved therapy
  355. Repairing extracellular aging and glycation
  356. Targeting the retinal microcirculation to treat diabetic sight problems
  357. Modification of the effect of glycemic status on aortic distensibility by age in the multi-ethnic study of atherosclerosis
  358. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis
  359. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy
  360. Anti-age antibodies and markers of oxidative stress in spontaneously hypertensive rats at different ages
  361. Oxidative stress and uremia
  362. A critical appraisal of erectile function in animal models of diabetes mellitus
  363. Renal nerve ablation reduces augmentation index in patients with resistant hypertension
  364. Non-enzymatic glycation of aminotransferases and the possibilities of its modulation
  365. Association of elevated apoA-I glycation and reduced HDL-associated paraoxonase1, 3 activity, and their interaction with angiographic severity of coronary …
  366. The stroke volume/pulse pressure ratio predicts coronary heart disease mortality in a population of elderly men
  367. Effect of ageing on left ventricular compliance and distensibility in healthy sedentary humans
  368. Aqueous extract of glucoraphanin-rich broccoli sprouts inhibits formation of advanced glycation end products and attenuates inflammatory reactions in …
  369. Advanced glycation endproduct-induced diabetic complications
  370. Future strategies for the treatment of diastolic heart failure
  371. Recently Published Works
  372. Hypertension and chronic kidney disease: respective contribution of mean and pulse pressure and arterial stiffness
  373. Ezrin contributes to impaired podocyte migration and adhesion caused by advanced glycation end products
  374. Therapeutic interventions for advanced glycation-end products and its receptor-mediated cardiovascular disease
  375. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a …
  376. Update on the treatment of diabetic retinopathy
  377. Inhibitory Potency of C-glycosyl Flavonoids from Morus sp. on Advanced Glycation End Products
  378. Advanced glycation: how are we progressing to combat this web of sugar anomalies in diabetic nephropathy
  379. Glucose, insulin and potential strategies of vascular stiffening
  380. Renoprotective antioxidant effect of alagebrium in experimental diabetes
  381. A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: common downstream endpoints achieved through …
  382. Abdominal aortic aneurysms and diabetes mellitus
  383. The year in hypertension
  384. Systolic hypertension in the elderly: arterial wall mechanical properties and the renin–angiotensin–aldosterone system
  385. DNA-aptamers raised against AGEs as a blocker of various aging-related disorders
  386. 24 Carotid intima–media thickness and arterial stiffness: indicators of cardiovascular risk and modifications by treatment
  387. Heart Failure with Preserved Ejection Fraction: Current Management and Future Strategies
  388. Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction
  389. Arterial stiffness
  390. Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients …
  391. The axis AGE-RAGE-soluble RAGE and oxidative stress in chronic kidney disease
  392. Arterial compliance
  393. Pharmacological and non-pharmacological treatment of endothelial dysfunction: relevance to diabetes
  394. Inhibitory activities of kaempferol against methylglyoxal formation, intermediate of advanced glycation end products
  395. Macrophages and diabetic nephropathy
  396. Ventriculovascular coupling in systolic and diastolic heart failure
  397. Assessing the potential of carboxylic acids as inhibitors of glycation
  398. Measures of arterial stiffness and wave reflection are associated with walking distance in patients with peripheral arterial disease
  399. Pharmaceutical medicine is an evolving discipline and research and development activity within the field is high. This section of the journal is intended to help you …
  400. Natriuretic peptide-guided therapy for heart failure: ready for “battle” or too “scarred” by the challenges of trial design?
  401. Sulforaphane reduces advanced glycation end products (AGEs)-induced inflammation in endothelial cells and rat aorta
  402. Health Library
  403. Tag: LYSOCLEAR
  404. Proteome wide reduction in AGE modification in streptozotocin induced diabetic mice by hydralazine mediated transglycation
  405. Emerging role of epigenetics and miRNA in diabetic cardiomyopathy
  406. Fully Atomistic Modelling of Collagen Cross-linking
  407. RAGE: a novel target for drug intervention in diabetic vascular disease
  408. Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease
  409. Vascular stiffening and arterial compliance: implications for systolic blood pressure
  410. Vascular stiffness and aging in HIV
  411. 21. Glycation-An imperative target in diabetes and complications
  412. Antioxidation and antiglycation of Fagopyrum tataricum ethanol extract
  413. Dynamic Changes in Myocardial Matrix and Relevance to Disease
  414. Relation between glycemia level and common carotid artery intima-media thickness in females
  415. Longitudinal analysis of low-molecular weight fluorophores in type 1 diabetes mellitus
  416. Glucose, Insulin and Potential
  417. Metabolic and biochemical stressors in diabetic cardiomyopathy
  418. International Research Journal of Ophthalmology
  419. Arterial stiffness, vascular calcification and bone metabolism in chronic kidney disease
  420. Advanced glycation end products (AGEs) increase renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN)
  421. Role of serum biomarkers in early detection of diabetic cardiomyopathy in the West Virginian population
  422. Effect of lecithin: cholesterol acyltransferase on the formation of cross-linked apolipoprotein AI
  423. Treatment of hypertensive left ventricular hypertrophy
  424. To AGE or not to age. The effect of physical activity and advanced glycation end-products (AGEs) on the vasculature in older individuals
  425. Pharmacological and non-pharmacological treatment of endothelial dysfunction: relevance to diabetes
  426. Cardiovascular calcifications in old age: mechanisms and clinical implications
  427. Arterial stiffness in chronic kidney disease: a modifiable cardiovascular risk factor?
  428. Deleterious Consequences of Dietary Advanced Glycation End Products on Human Health Due to Oxidative Stress and Inflammation
  429. Targeting Blood Pressure Lowering and the Sympathetic Nervous System
  430. Oxidative stress in early diabetic nephropathy: fueling the fire
  431. New horizons in the management of cardiovascular disease
  432. Elevation of serum methylglyoxal may be used as a screening marker in oral premalignant lesions.
  433. Circulating endothelial progenitor cells and erectile dysfunction: possibility of nutritional intervention?
  434. Pioglitazone attenuates vascular fibrosis in spontaneously hypertensive rats
  435. Antihypertensive agents and arterial stiffness: relevance to reducing cardiovascular risk in the chronic kidney disease patient
  436. Neurite regeneration in adult rat retinas exposed to advanced glycation end-products and regenerative effects of neurotrophin-4
  437. Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy
  438. Cardiac aging–a review
  439. Glycoxidation and wound healing in diabetes: an interesting relationship
  440. The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature
  441. Parkinsonism-associated protein DJ-1/Park7 is a major protein deglycase that repairs methylglyoxal-and glyoxal-glycated cysteine, arginine, and lysine residues
  442. The role of advanced glycation end products in vascular aging: which parameter is the most suitable as a biomarker?
  443. Cucumber Juice Treatment to the Decrease of Systolic and Diastolic Blood Pressure
  444. MRI and echocardiographic assessment of the diastolic dysfunction of normal aging: altered LV pressure decline or load?
  445. Novel insights in the treatment of diabetic nephropathy
  446. Browsed by Tag: Cellular senescence
  447. Ascending aortic blood pressure waveform is related to coronary atherosclerosis in hypertensive as well as in normotensive subjects
  448. Role of exercise and metabolism in heart failure with normal ejection fraction
  449. Signal transduction pathways in mouse microglia N‐11 cells activated by advanced glycation endproducts (AGEs)
  450. Advanced glycation end products in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction
  451. Diabetic myocardial disease: pathophysiology, early diagnosis and therapeutic options
  452. Browsed by Month: December 2017
  453. Erectile dysfunction in the type II diabetic db/db mouse: impaired venoocclusion with altered cavernosal vasoreactivity and matrix
  454. Pigment epithelium‑derived factor inhibits advanced glycation end product‑induced proliferation, VEGF and MMP‑9 expression in breast cancer cells via interaction …
  455. Diabetes and advanced glycation end products
  456. Role of ligands of receptor for advanced glycation end products (RAGE) in peripheral artery disease
  457. The heterogenic tumor microenvironment of hepatocellular carcinoma and prognostic analysis based on tumor neo-vessels, macrophages and α-SMA
  458. In vitro screening on amyloid beta modulation of aqueous extracts from plant seeds
  459. Plasma advanced glycation end products (AGEs) and NF-κB activity are independent determinants of diastolic and pulse pressure
  460. Commentary on some recent theses relevant to combating aging: February 2014
  461. Imaging of functional and structural alterations of large arteries after acute ischaemic atherothrombotic stroke or acute coronary syndromes
  462. Molecular effects of advanced glycation end products on cell signalling pathways, ageing and pathophysiology
  463. N-butanol extracts of Morinda citrifolia suppress advanced glycation end products (AGE)-induced inflammatory reactions in endothelial cells through its anti …
  464. Alzheimer’s disease and type 2 diabetes: different pathologies and same features
  465. Arterial aging
  466. To what extent can coronary calcification and arterial stiffness be influenced by the nephrologist?
  467. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering
  468. Poly (adenosine 5′-diphosphate-ribose) polymerase inhibition counteracts multiple manifestations of experimental type 1 diabetic nephropathy
  469. Glycation, antiglycation, and deglycation: Their role in aging mechanisms and geroprotective effects (literature review)
  470. Advances in the non-invasive assessment of vascular dysfunction in metabolic syndrome and diabetes: focus on endothelium, carotid mechanics and renal vessels
  471. Extracellular protease activation and unraveling of the myocardial interstitium: critical steps toward clinical applications
  472. Age-related vascular stiffening: causes and consequences
  473. Arterial stiffness and cardiovascular risk in hypertension
  474. Role of receptor for advanced glycation end products (RAGE) and its ligands in cancer risk
  475. Variants of COL3A1 are associated with the risk of stroke recurrence and prognosis in the Chinese population: a prospective study
  476. Metabolic dysfunction in diabetic cardiomyopathy
  477. Pathological Role of AGEs in Osteoporosis
  478. Switching dipeptidyl peptidase-4 inhibitors to tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2 improve arterial stiffness evaluated by cardio-ankle …
  479. New approaches to the treatment of nephropathy in diabetes
  480. Serum 25-hydroxyvitamin D3 is associated with advanced glycation end products (AGEs) measured as skin autofluorescence: The Rotterdam Study
  481. Protein carbonylation, cellular dysfunction, and disease progression
  482. Special clinical considerations of beta-blocker treatment
  483. Laboratory forum: experimental models of Peyronie’s disease. Implications for new therapies
  484. Agents that modulate peritoneal membrane structure and function
  485. Advanced glycation end-products are associated with the presence and severity of paratonia in early stage Alzheimer disease
  486. Vascular endothelial dysfunction in diabetic cardiomyopathy: pathogenesis and potential treatment targets
  487. Advanced glycation end products and their receptors in serum of patients with type 2 diabetes
  488. Browsed by Tag: Rejuvenation Biotechnologies
  489. A Receptor‐Based Bioadsorbent to Target Advanced Glycation End Products in Chronic Kidney Disease
  490. Compromised mechanical homeostasis in arterial aging and associated cardiovascular consequences
  491. Impact of non-enzymatic glycation in neurodegenerative diseases: Role of natural products in prevention
  492. Association of plasma pentosidine concentrations with renal function in kidney graft recipients
  493. Glycation of aspartate aminotransferase by methylglyoxal, effect of hydroxycitric and uric acid
  494. Advanced glycation end products: a molecular target for vascular complications in diabetes
  495. Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: a novel marker of vascular complications in high-risk patients …
  496. Serum levels of protein-bound methylglyoxal-derived hydroimidazolone-1 are independently correlated with asymmetric dimethylarginine
  497. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes
  498. Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease
  499. Management of left ventricular diastolic heart failure: is it only blood pressure control?
  500. Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment
  501. AGE and RAGE inhibitors in the treatment of diabetic retinopathy
  502. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding
  503. Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation
  504. Advanced glycation end products and diabetic retinopathy
  505. Pulse wave velocity—a useful tool for cardiovascular surveillance in pre-dialysis patients
  506. Arterial stiffness–A measurable vascular marker in clinical practice
  507. Pulse wave analysis and diabetes mellitus. A systematic review.
  508. A review on mechanism of inhibition of advanced glycation end products formation by plant derived polyphenolic compounds
  509. Non-invasive measurements of arterial function: What? When? Why should we use them?
  510. Cardiorenal syndrome type 4: From chronic kidney disease to cardiovascular impairment
  511. Phytochemicals against advanced glycation end products (AGEs) and the receptor system
  512. IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies
  513. Glycation and tubulointerstitial injury; in vitro and in vivo studies
  514. From ‘optimal’to ‘borderline’blood pressure in subjects under chronic antihypertensive therapy
  515. Rosuvastatin slows the development of diastolic dysfunction in calcific aortic stenosis
  516. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension
  517. PLC/CAMK IV–NF-κB involved in the receptor for advanced glycation end products mediated signaling pathway in human endothelial cells
  518. Targeting inflammation in diabetic nephropathy: a tale of hope
  519. Effects of vitamin D restricted diet administered during perinatal and postnatal periods on the penis of Wistar rats
  520. Diabetes and kidney disease
  521. Soluble receptor for advanced glycation end products and increased aortic stiffness in the general population
  522. The association of non-invasive skin autofluorescence measurements with cardiovascular and all-cause mortality in hemodialysis patients: a meta-analysis
  523. Novel pharmacological treatments for heart failure
  524. Smooth muscle cell pathophysiology and advanced glycation end products (AGEs)
  525. Regulation of matrix synthesis, remodeling and accumulation in glomerulosclerosis
  526. Selective Substitution of 31/42–OH in Rapamycin Guided by an in Situ IR Technique
  527. The Impact of Diabetic Renal Disease
  528. A tense situation: forcing tumour progression
  529. Novel drugs and their targets in the potential treatment of diabetic retinopathy
  530. Early functional and structural microvascular changes in hypertension related to aging
  531. Soluble receptor for advanced glycation end-products independently influences individual age-dependent increase of arterial stiffness
  532. Casein Hydrolysate Containing Milk-Derived Peptides Reduces Facial Pigmentation Partly by Decreasing Advanced Glycation End Products in the Skin: A …
  533. Diabetes mellitus-associated atherosclerosis
  534. Future Therapies in Diastolic Heart Failure
  535. Large arteries and the kidney
  536. Aged garlic has more potent antiglycation and antioxidant properties compared to fresh garlic extract in vitro
  537. Recent advances in diabetic nephropathy
  538. Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging
  539. The Effect Of Foam Rolling On Pulse Wave Velocity
  540. Glycation-induced protein aggregation and cellular toxicity: an insight into the disease realm of high dietary sugar intake
  541. A concise appraisal of lipid oxidation and lipoxidation in higher plants
  542. Diabetic Cardiomyopathy: Current Status
  543. 8th EASD/JDRF OXFORD WORKSHOP
  544. Current and future initiatives for vascular health management in clinical practice
  545. Microvessel vascular smooth muscle cells contribute to collagen type I deposition through ERK1/2 MAP kinase, αvβ3-integrin, and TGF-β1 in response to ANG II and …
  546. Alagebrium inhibits neointimal hyperplasia and restores distributions of wall shear stress by reducing downstream vascular resistance in obese and diabetic rats
  547. Association of physical fitness with skin autofluorescence-derived advanced glycation end products in children
  548. Breakthrough in heart failure with preserved ejection fraction: are we there yet?
  549. Albumin Exchange in Alzheimer’s Disease: Might CSF Be an Alternative Route to Plasma?
  550. Effects of adipose-derived stem cells plus insulin on erectile function in streptozotocin-induced diabetic rats
  551. Diabetic cardiomyopathy
  552. Cardiovascular biomarkers in CKD: pathophysiology and implications for clinical management of cardiac disease
  553. Preservation of pressure-induced cutaneous vasodilation by limiting oxidative stress in short-term diabetic mice
  554. Diastology E-Book: Clinical Approach to Diastolic Heart Failure
  555. Pyridoxamine prevents age-related aortic stiffening and vascular resistance in association with reduced collagen glycation
  556. Aging biology in the kidney
  557. Pathogenesis and pathophysiology of diabetic nephropathy
  558. Diastolic heart failure: progress, treatment challenges, and prevention
  559. Cellular therapy using microglial cells
  560. Hypertension, systolic blood pressure, and large arteries
  561. Browsed by Tag: Unity Biotechnology
  562. The melibiose-derived glycation product mimics a unique epitope present in human and animal tissues
  563. Matrix metalloproteinases are possible targets in monocrotaline-induced pulmonary hypertension: investigation of anti-remodeling effects of alagebrium and …
  564. High-density lipoprotein at the interface of type 2 diabetes mellitus and cardiovascular disorders
  565. Treatment of heart failure with normal ejection fraction: an inconvenient truth!
  566. Annual update 2004/2005-Treatment of cardiovascular disorders
  567. Diabetic nephropathy: where hemodynamics meets metabolism
  568. Will new antihypertensive drugs emerge? Part 1
  569. Can we justify goal blood pressure of< 140/90 mm Hg in most hypertensives?
  570. Pathological role of advanced glycation end products (AGEs) and their receptor axis in atrial fibrillation
  571. Methylglyoxal promotes oxidative stress and endothelial dysfunction
  572. The roles of protein glycation, glycoxidation, and advanced glycation end-product formation in diabetes-induced atherosclerosis
  573. Advanced glycation end products and cardiovascular disease
  574. Functional decorations: post-translational modifications and heart disease delineated by targeted proteomics
  575. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus
  576. Pathologic role of dietary advanced glycation end products in cardiometabolic disorders, and therapeutic intervention
  577. Coevolution of the tumor microenvironment revealed by quantum dot-based multiplexed imaging of hepatocellular carcinoma
  578. Anagliptin, a dipeptidyl peptidase-4 inhibitor ameliorates arterial stiffness in association with reduction of remnant-like particle cholesterol and alanine transaminase …
  579. Sarcopenia in chronic kidney disease: Focus on advanced glycation end products as mediators and markers of oxidative stress
  580. Mimetics of hormetic agents: stress-resistance triggers
  581. Daily monitoring of arterial stiffness in children with end-stage renal disease
  582. Daily Monitoring of Arterial Stiffness in Children with End-stage Renal Disease
  583. Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocin‐treated, apolipoprotein E‐deficient mice
  584. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria
  585. Clinical implications for patients with heart failure with preserved ejection fraction
  586. The Potential Role of Gene Editing in the Aging of Somatic cells: A Review of Literature
  587. Vascular complications in diabetes mellitus: the role of endothelial dysfunction
  588. Toxicity of protein and DNA-AGEs in neurodegenerative diseases (NDDs) with decisive approaches to stop the deadly consequences
  589. Mechanism for the development of bone disease in diabetes: increased oxidative stress and advanced glycation end products
  590. Emerging drugs and indications for cardio-metabolic disorders in people with severe mental illness
  591. Normalizing aberrant vasculature characteristics generated by elevated extracellular matrix stiffness
  592. Meta-analysis of the quantitative relation between pulse pressure and mean arterial pressure and cardiovascular risk in patients with diabetes mellitus
  593. Hypertension, diabetes type II, and their association: role of arterial stiffness
  594. Advanced glycation end-product peptides are associated with impaired renal function, but not with biochemical markers of endothelial dysfunction and inflammation …
  595. Renal effects of C-peptide in experimental type-1 diabetes mellitus
  596. Carbohydrate Directed Photoaffinity Labelling
  597. Role of PPAR-δ in Diabetic Cardiomyopathy
  598. Hypertension: Current trends and future perspectives
  599. Oxidation as an important factor of protein damage: Implications for Maillard reaction
  600. Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
  601. Cellular Noise and The Aging Process
  602. Effects of garlic (Allium sativum) extract on the expression of receptor for advanced glycation end products and proinflammatory cytokines secretion in peripheral blood …
  603. Arteries and veins
  604. Pathophysiology of the diabetic kidney
  605. L-carnosine and its Derivatives as New Therapeutic Agents for the Prevention and Treatment of Vascular Complications of Diabetes
  606. Medical bioremediation of age-related diseases
  607. Salidroside ameliorates endothelial inflammation and oxidative stress by regulating the AMPK/NF-κB/NLRP3 signaling pathway in AGEs-induced HUVECs
  608. Development of pharmacological screening method for evaluation of effect of drug on elevated pulse pressure and arterial stiffness
  609. Role of changes in state of bound water and tissue stiffness in development of age-related diseases
  610. Diabetic Cardiomyopathy: Insights into Pathogenesis, Diagnostic Challenges, and Therapeutic Options
  611. Advances in Heart Failure
  612. Rosiglitazone inhibits angiotensin II-induced CTGF expression in vascular smooth muscle cells––Role of PPAR-γ in vascular fibrosis
  613. Plasma Catestatin Levels and Advanced Glycation End Products in Patients on Hemodialysis
  614. Trans-resveratrol mitigates type 1 diabetes-induced oxidative DNA damage and accumulation of advanced glycation end products in glomeruli and tubules of rat …
  615. The reality of aging viewed from the arterial wall
  616. Diabetic neuropathy: mechanisms to management
  617. Cross linkage between oxidative stresses in diabetic nephropathy: An updated review
  618. Clinical presentation, treatment, and prognosis of heart failure in diabetes
  619. SENS Foundation: Accelerating Progress Toward Biomedical Rejuvenation
  620. Protective role of sulphoraphane against vascular complications in diabetes
  621. Cell replacement in future rejuvenation therapies
  622. Diabetic cardiomyopathy: signaling defects and therapeutic approaches
  623. Advanced glycation end products: New clinical and molecular perspectives
  624. Hyperglycemia impairs atherosclerosis regression in mice
  625. Beneficial cardiac effects of caloric restriction are lost with age in a murine model of obesity
  626. Preventive strategies for diabetic nephropathy
  627. Effects of garlic (Allium sativum) extract on the expression of receptor for advanced glycation end products and proinflammatory cytokines secretion in …
  628. New molecular histopathologic insights into the pathogenesis of age-related macular degeneration
  629. Imaging in diabetic cardiomyopathy
  630. Natural compounds with potential antioxidant activity; in vitro study in a model of protein glycoxidation
  631. Rise and fall of elastic fibers from development to aging. Consequences on arterial structure-function and therapeutical perspectives
  632. Serum levels of growth differentiation factor 11 are independently associated with low hemoglobin values in hemodialysis patients
  633. Hypertrophic cardiomyopathy
  634. Constitutive interpretation of arterial stiffness in clinical studies: a methodological review
  635. High Density Lipoproteins and Diabetes
  636. Browsed by Tag: DNA
  637. Diastolic dysfunction in hypertension
  638. Increased central arterial stiffness after spinal cord injury: contributing factors, implications, and possible interventions
  639. Microvessels Vascular Smooth Muscle Cells Contribute to Collagen Type-I deposition Through ERK1/2 MAP-kinase, αvβ3-Integrin and TGFβ1 in Response to …
  640. Treatment with the herbal medicine, naoxintong improves the protective effect of high‑density lipoproteins on endothelial function in patients with type 2 …
  641. Exercise training as therapy for heart failure: current status and future directions
  642. Factors influencing crosslink formation in muscle tissue
  643. Echocardiographic Evaluation of Cardiac Function in Patients with Newly Detected Type 2 Diabetes Mellitus
  644. Oral administration of spa-derived green alga improves insulin resistance in overweight subjects: Mechanistic insights from fructose-fed rats
  645. Central artery stiffness and thoracic aortopathy
  646. Regulation and bioactivity of the CCN family of genes and proteins in obesity and diabetes
  647. Glycation and antioxidants: hand in the glove of antiglycation and natural antioxidants
  648. Recent advances in Raman spectroscopy of proteins for disease diagnosis
  649. Browsed by Tag: diseases
  650. Novel therapies in acute and chronic heart failure
  651. Associations between structural and functional changes to the kidney in diabetic humans and mice
  652. Calcified splenic artery
  653. Cardiovascular ageing in health sets the stage for cardiovascular disease
  654. The paraoxonase 1 (PON1), platelet-activating factor acetylohydrolase (PAF-AH) and dimethylarginine dimethylaminohydrolase (DDAH) activity in the metformin …
  655. Role of Amino Acids on Prevention of Nonenzymatic Glycation of Lens Proteins in Senile and Diabetic Cataract
  656. Potential properties of plant sprout extracts on amyloid β
  657. Diabetic cardiovascular disease induced by oxidative stress
  658. Skin aging handbook: an integrated approach to biochemistry and product development
  659. Present insights on cardiomyopathy in diabetic patients
  660. Diabetes and Pancreatic Cancer—A Dangerous Liaison Relying on Carbonyl Stress
  661. Investigation of circulating RAGE in patients with cardiovascular disease
  662. Applied healthspan engineering
  663. Arterial de-stiffing Drugs: Which Promising Therapeutic Agent is Useful?
  664. Diabetic HDL is dysfunctional in stimulating endothelial cell migration and proliferation due to down regulation of SR-BI expression
  665. Low glial angiotensinogen improves body habitus, diastolic function, and exercise tolerance in aging male rats
  666. Efficacy of sitagliptin in retarding the progression of albuminuria and assessing its safety and efficacy in patients with diabetic nephropathy
  667. Pacing and Diastolic Heart Failure
  668. Assessment of protein glycoxidation in ventricular tissues
  669. Diet-Derived Advanced Glycation End Products (dAGEs) Induce Proinflammatory Cytokine Expression in Cardiac and Renal Tissues of Experimental Mice: Protective …
  670. Age-related changes in the mechanical properties of large arteries
  671. Extracellular matrix
  672. New insights into arterial stiffening: does sex matter?
  673. Plant-derived agents with anti-glycation activity
  674. Cardiac tissue remodeling in healthy aging: the road to pathology
  675. Receptor for AGEs (RAGE) as mediator of NF-kB pathway activation in neuroinflammation and oxidative stress
  676. Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research
  677. The clinical dilemma of heart failure with preserved ejection fraction: an update on pathophysiology and management for physicians
  678. Modification of the Glycemic Status on Aortic Distensibility by Age in the Multi-Ethnic Study of Atherosclerosis
  679. Environmental health risk perception of hydraulic fracturing in the US
  680. LIVIU KLEIN, MD, MS ROBERT O. BONOW, MD
  681. Metabolic effects of metformin in the failing heart
  682. Chronic heart failure in the elderly: a current medical problem
  683. Redox control of renal function and hypertension
  684. A concise appraisal of lipid oxidation and lipoxidation in higher plants
  685. Pathogenesis of renal microvascular complications in diabetes mellitus
  686. Treating Arterial Ageing in Patients with Diabetes: From Mechanisms to Effective Drugs
  687. Nitrite modification of extracellular matrix alters CD46 expression and VEGF release in human retinal pigment epithelium
  688. Developing and characterization of bioadsorbent for extracorporeal blood purification
  689. Biocompatibility of icodextrin
  690. Current therapies and emerging targets for the treatment of diabetes
  691. Lipoprotein glycation in diabetes mellitus
  692. Treatment of Heart Failure With Normal Ejection Fraction
  693. Alteration of nitric oxide-mediated blood flow regulation in diabetes mellitus
  694. Eye lens in aging and diabetes: effect of quercetin
  695. Dietary interventions to reduce advanced glycation endproducts (AGEs)
  696. Nöronal Plastisite ve Nörodejeneratif Hastalıklarda NF-κB’nin Rolü
  697. Alterations in circulatory function
  698. Twenty-five years since the discovery of endothelium-derived relaxing factor (EDRF): does a dysfunctional endothelium contribute to the development of type 2 …
  699. Aging and the Frontier Ahead
  700. The thiamine analogue and advanced glycation endproducts crosslink breaker ALT-711 does not interfere with transketolase activity
  701. Current and future antihypertensive drugs in post-transplant hypertension and related patents
  702. Preventive aspects in peripheral artery disease
  703. Prevention of advanced glycation end-products formation in diabetic rats through beta-cell modulation by Aegle marmelos
  704. Maculoplasty for age-related macular degeneration: reengineering Bruch’s membrane and the human macula
  705. N⁶-formylation of lysine: a pathological secondary modification of proteins
  706. Browsed by Tag: Aubrey de Grey
  707. Early detection and significance of structural cardiovascular abnormalities in patients with Type 2 diabetes mellitus
  708. Browsed by Tag: cancer
  709. New antihypertensive drugs under development
  710. Effects of Age and Immune Dysfunction on the Cardiac Extracellular Matrix and Diastolic Function
  711. AGE/RAGE signaling-mediated endoplasmic reticulum stress and future prospects in non-coding RNA therapeutics for diabetic nephropathy
  712. Protective effects of desacyl ghrelin on doxorubicin-induced and diabetic cardiomyopathy
  713. Role of methylglyoxal in the pathogenesis of hypertension
  714. Bone quality analysis of jaw bones in individuals with type 2 diabetes mellitus—post mortem anatomical and microstructural evaluation
  715. Is endothelial dysfunction the one to blame in Heart Failure with Preserved Ejection Fraction?
  716. Protective effect of some natural products on glucose or methylglyoxal induced glycation of superoxide dismutase
  717. PROTECTIVE EFFECT OF SOME NATURAL PRODUCTS ON GLUCOSE OR METHYLGLYOXAL INDUCED GLYCATION OF SUPEROXIDE DISMUTASE
  718. Pleiotropic consequences of metabolic stress for the major histocompatibility complex class II molecule antigen processing and presentation machinery
  719. Effects of phosphate binding with sevelamer carbonate on cardiovascular structure and function in patients with early chronic kidney disease
  720. Finite element modeling of collagen fibers in the mechanical interaction between cells and the extracellular matrix
  721. Methylglyoxal-induced increase in peroxynitrite and inflammation related to diabetes
  722. Meta-profiles of gene expression during aging: limited similarities between mouse and human and an unexpectedly decreased inflammatory signature
  723. Traditional, Nontraditional, and Uremia-Related Threats for Cardiovascular Disease in Chronic Kidney Disease
  724. Evolving insights into the pathophysiology of diabetic neuropathy: implications of malfunctioning glia and discovery of novel therapeutic targets
  725. Bibliography Current World Literature Vol 19 No 4 July 2004
  726. Stromal regulation of vessel stability by MMP14 and TGFβ
  727. Traditional, Nontraditional, and Uremia-Related Threats for Cardiovascular Disease in Chronic Kidney
  728. The efficacy of dry beans (Phaseolus vulgaris L.) for improving vascular function: exploring seed coat colour as an indicator of functionality
  729. The compensatory enrichment of sphingosine-1-phosphate harbored on glycated high-density lipoprotein restores endothelial protective function in type 2 …
  730. The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities
  731. Stimulatory effects of non-enzymatic glycation on fibronectin matrix assembly
  732. The RAGE Axis
  733. Aging and Cardiovascular Risk
  734. Regulation of Focal Adhesion Dynamics by a Kinesin Motor Kid/KIF22/Kinesin-10
  735. Myocardial contraction fraction, diabetes and heart failure: The multi ethnic study of atherosclerosis
  736. Positions held
  737. Vascular function and structure in the rat aorta
  738. Regulation of aging in yeast by glycation inhibitors
  739. Atomic Force Microscopy-based essay for biomedical applications
  740. The impact of the diabetic state on gingival tissues: The role of tetracyclines in disease management
  741. Immnochemical Studies on Glycated Human Serum Albumin: Role of Aminoguanidine and Thymoquinone in the Reduction of Glycation Products in Diabetes …
  742. Perturbation of cellular and vascular function by hyperglycaemia and hyperlipidaemia and their role in cardiovascular disease
  743. Psychosocial and Oxidative Stress and Health of Adults
  744. Comprehensive nanorobotic control of human morbidity and aging
  745. Relationship between a trial fibrillation and hypertension in rats
  746. Antioxidant and Antiglycation Properties of Fifteen Cultivated and Wild Vigna Species
  747. Vascular Stem and Progenitor Cells in Diabetic Complications
  748. Rôle du système rénine-angiotensine intrarénal dans l’hypertension et les dommages rénaux chez les souris transgéniques diabétiques
  749. Renal immunology and pathology
  750. Arterial stiffness and subclinical atherosclerosis in elderly participants from the Cardiovascular Health Study
  751. Emerging drugs for diabetic nephropathy
Related Posts

Anti Aging

Skeletal Muscle Hypertrophy (The Science Of Building Muscle)

Infectobesity

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping